Daniel E Meyers
Overview
Explore the profile of Daniel E Meyers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
269
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Meyers D, Rittberg R, Dawe D, Banerji S
Curr Oncol
. 2024 Sep;
31(9):5498-5515.
PMID: 39330035
Since the initial US FDA approval of an immune checkpoint inhibitor (ICI) for the treatment of non-oncogene-driven non-small-cell lung cancer (NSCLC) nine years ago, this therapeutic strategy has been cemented...
2.
Abbott A, Meyers D, Elmi-Assadzadeh G, Stukalin I, Marro A, Puloski S, et al.
Front Immunol
. 2024 Jul;
15:1379056.
PMID: 38957472
Background: Bone metastases (BoMs) are prevalent in patients with metastatic non-small-cell lung cancer (NSCLC) however, there are limited data detailing how BoMs respond to immune checkpoint inhibitors (ICIs). The purpose...
3.
Gupta M, Stukalin I, Meyers D, Heng D, Monzon J, Cheng T, et al.
Front Oncol
. 2024 Jun;
14:1385425.
PMID: 38884085
Background: The association between objective imaging response and first line immune checkpoint inhibitor (ICI) therapy regimes in advanced melanoma remains uncharacterized in routine practice. Methods: We conducted a multi-center retrospective...
4.
Cook S, Samuel V, Meyers D, Stukalin I, Litt I, Sangha R, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2352302.
PMID: 38236598
Importance: Immune-related adverse events (irAEs) secondary to immune checkpoint inhibitor (ICI) therapy reportedly improve overall survival (OS) in patients with non-small cell lung cancer (NSCLC). However, studies have been small...
5.
Jenei K, Meyers D
BMJ Open
. 2023 Oct;
13(10):e066378.
PMID: 37844982
Objective: To examine characteristics of clinician input to the pan-Canadian Oncology Drug Review (pCODR) for cancer drug funding recommendations from 2016 to 2020. Design, Setting And Participants: Descriptive, cross-sectional study...
6.
Meyers D, Pasternak M, Dolter S, Grosjean H, Lim C, Stukalin I, et al.
JTO Clin Res Rep
. 2023 Apr;
4(4):100482.
PMID: 37090101
Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology...
7.
Stukalin I, Navani V, Gupta M, Ruan Y, Boyne D, OSullivan D, et al.
Oncologist
. 2023 Apr;
28(9):812-822.
PMID: 37011230
Background: Risk stratification tools for patients with advanced melanoma (AM) treated with immune checkpoint inhibitors (ICI) are lacking. We identified a new prognostic model associated with overall survival (OS). Patients...
8.
Navani V, Meyers D, Ruan Y, Boyne D, OSullivan D, Dolter S, et al.
Clin Lung Cancer
. 2023 Feb;
24(3):e152-e159.
PMID: 36774234
Introduction/background: Immune checkpoint inhibitors (ICI) have revolutionized non-small cell lung cancer (NSCLC). We aimed to identify baseline characteristics, that are prognostic factors for overall survival (OS) in patients with NSCLC...
9.
Watson A, Goutam S, Stukalin I, Ewanchuk B, Sander M, Meyers D, et al.
JAMA Netw Open
. 2022 Dec;
5(12):e2245596.
PMID: 36480204
Importance: Immune-related adverse events (irAEs) due to immune checkpoint blockade (ICB) have been shown to be positively associated with survival. Among patients with metastatic melanoma, evidence supporting this association has...
10.
Goutam S, Stukalin I, Ewanchuk B, Sander M, Ding P, Meyers D, et al.
Curr Oncol
. 2022 Oct;
29(10):7695-7704.
PMID: 36290885
Immune checkpoint inhibitors (ICIs) for treatment of metastatic melanoma (MM) offer lasting overall survival (OS) benefit in a subset of patients. However, outcomes remain poor for non-responders. Clinical predictors of...